Holen Sie sich die Stockscreener-App
226.69
1.12%
-2.56
Handel nachbörslich:
228.00
1.31
+0.58%
Schlusskurs vom Vortag:
$229.25
Offen:
$227.91
24-Stunden-Volumen:
368.76K
Relative Volume:
0.56
Marktkapitalisierung:
$13.92B
Einnahmen:
$823.12M
Nettoeinkommen (Verlust:
$-253.97M
KGV:
-54.01
EPS:
-4.1973
Netto-Cashflow:
$51.45M
1W Leistung:
+3.82%
1M Leistung:
-5.80%
6M Leistung:
+7.52%
1J Leistung:
+58.89%
1-Tages-Spanne:
$226.44
$230.89
1-Wochen-Bereich:
$218.82
$235.62
52-Wochen-Spanne:
$124.06
$248.60
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare ASND vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
226.69 | 14.07B | 823.12M | -253.97M | 51.45M | -4.1973 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-17 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Eingeleitet | Stifel | Buy |
| 2023-12-20 | Eingeleitet | Jefferies | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
| 2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-08-30 | Fortgesetzt | Berenberg | Buy |
| 2022-03-28 | Fortgesetzt | Wedbush | Outperform |
| 2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Market Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Fortgesetzt | Stifel | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Eingeleitet | Stifel | Buy |
| 2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
| 2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten
Ascendis Pharma A/S (ASND) stock price, news, quote and history - Yahoo Finance Singapore
How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Strong Multi Year Shareholder Returns - Sahm
Ascendis Pharma (ASND) Is Down 5.8% After New Two-Year YUVIWEL Achondroplasia Data Release – Has The Bull Case Changed? - Sahm
Avoro Capital Advisors LLC Has $1.02 Billion Stock Holdings in Ascendis Pharma A/S $ASND - Defense World
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
This Biopharma Stock Flirts With Buy Point After New FDA Approval - Investor's Business Daily
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 - Sahm
Ascendis Wins FDA Approval For Rare Disease Therapy - Sahm
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - Sahm
Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives - Sahm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewswire Inc.
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Sahm
Ascendis Pharma (ASND) Is Up 5.2% After Revenue Jumps And Losses Narrow In 2025 Results - Sahm
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth - Finviz
Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)? - Sahm
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Sahm
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript - The Globe and Mail
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss - Chartmill
Ascendis Pharma Earnings Report: Q4 Overview - Sahm
Did Health Canada’s Yorvipath Approval Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - Sahm
Hershey Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Assessing Ascendis Pharma (ASND) Valuation After Health Canada Approval For Yorvipath - Sahm
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT - Finviz
ASCENDIS PHARMA A/SADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum - Chartmill
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharma’s (ASND) Investment Case? - Sahm
Ascendis Pharma ADR Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results - Sahm
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Ascendis Pharma A/S (ASND): A Bull Case Theory - Finviz
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma's (ASND) Investment Narrative? - Sahm
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 83 RS Rating - Investor's Business Daily
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Phase 2 Achondroplasia Results - Sahm
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Sahm
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan - ChartMill
Ascendis Pharma ADR Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Can you now get a good deal on Ascendis Pharma A/S ADR’s shares? - uspostnews.com
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Ascendis Pharma’s Price Surge Amid New Developments - StocksToTrade
Finanzdaten der Ascendis Pharma A S Adr-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):